GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Basic Sciences/Dengue Suppression by Male Wolbachia-Infected Mosquitoes: NEJM | March 2026
69

Dengue Suppression by Male Wolbachia-Infected Mosquitoes: NEJM | March 2026

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated March 1, 2026

Introduction

Dengue continues to emerge as a major global public health challenge, driven by rapid urbanisation, climate change, and the expansion of mosquito habitats. Conventional vector-control strategies such as insecticides, source reduction, and repellents have shown limited and often unsustained impact, while vaccine options remain suboptimal across all serotypes. This has led to growing interest in biologically innovative approaches. One such strategy involves infecting male Aedes aegypti mosquitoes with Wolbachia bacteria, which induces cytoplasmic incompatibility and prevents viable offspring when these males mate with wild-type females, thereby suppressing mosquito populations and potentially reducing dengue transmission.

Problem Statement

Despite multiple preventive strategies, dengue incidence continues to rise globally, highlighting a critical gap in effective, scalable, and sustainable vector-control interventions. While Wolbachia-based methods have shown promise in observational and limited trials, robust randomised evidence demonstrating real-world epidemiologic benefit—particularly using male-only sterile mosquito release (IIT-SIT approach)—has been lacking.

Summary

This large cluster-randomised trial in Singapore demonstrated that releasing Wolbachia-infected male mosquitoes significantly reduced both mosquito density and dengue incidence. Female mosquito abundance dropped markedly in intervention areas, and dengue positivity rates decreased from 21% in control clusters to 6% in intervention clusters. The intervention achieved a protective efficacy of approximately 71–72% after sustained exposure.

These findings provide strong real-world evidence that Wolbachia-based vector suppression is an effective, environmentally sustainable strategy for dengue control. This approach represents a major shift from chemical-based control toward biological population suppression, with potential scalability in urban settings worldwide.

Related Q&A

70

Molecularly Guided Therapy in HCC: Journal of Hepatology | March 2026

Introduction Advanced primary liver cancers, including hepatocellular carcinoma and cholangiocarcinoma, remain difficult to treat once they become refractory to standard systemic therapies. Survival outcomes are poor, and therapeutic...

71

Berberine and Cholestatic Liver Disease: Clinical and Molecular Hepatology | March 2026

Introduction Cholestatic liver disease (CLD) is a progressive condition characterised by impaired bile formation and flow, leading to bile accumulation, liver injury, and eventual cirrhosis or liver failure....

72

Obesity and Cancer: JAMA March 2026

Obesity is no longer viewed only as a metabolic disorder; it is now a major cancer-promoting state. This review explains how excess adiposity drives cancer through intertwined biologic...

73

PDE5A+ Cancer-Associated Fibroblasts in Gastric Cancer: Gut, March 2026

Introduction Gastric cancer remains one of the most lethal malignancies worldwide. The tumour microenvironment (TME)—particularly cancer-associated fibroblasts (CAFs)—plays a critical role in tumour progression, immune evasion, and resistance...

74

Bimagrumab + Semaglutide: BELIEVE STUDY: Nature Medicine | 2026

Introduction Most obesity therapies reduce body fat, but they also cause a meaningful loss of lean mass, including skeletal muscle. This matters because preserving muscle is important for...

75

TAF2 Drives Hepatocyte Survival in HCC: Hepatology March 26

Chromosome 8q amplification, a common genomic alteration in hepatocellular carcinoma (HCC), includes the gene TATA-box binding protein–associated factor 2 (TAF2), a key component of the TFIID basal transcription...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer